ECSP22049399A - C?lula vector adyuvante artificial con contenido de ny?eso?1 para usar en el tratamiento del c?ncer - Google Patents
C?lula vector adyuvante artificial con contenido de ny?eso?1 para usar en el tratamiento del c?ncerInfo
- Publication number
- ECSP22049399A ECSP22049399A ECSENADI202249399A ECDI202249399A ECSP22049399A EC SP22049399 A ECSP22049399 A EC SP22049399A EC SENADI202249399 A ECSENADI202249399 A EC SENADI202249399A EC DI202249399 A ECDI202249399 A EC DI202249399A EC SP22049399 A ECSP22049399 A EC SP22049399A
- Authority
- EC
- Ecuador
- Prior art keywords
- eso
- treatment
- cancer
- cell containing
- vector cell
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000002671 adjuvant Substances 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Un objetivo de la presente invenci?n es dar a conocer una c?lula aAVC?NY?ESO?1 cl?nicamente aplicable que expresa NY?ESO?1 de manera estable para usar las c?lulas aAVC?NY?ESO?1 en el tratamiento de pacientes con c?ncer que expresa NY?ESO?1. La presente invenci?n brinda, por ejemplo, una c?lula de origen humano que comprende un polinucle?tido que codifica CD1d y un polinucle?tido que codifica NY?ESO?1 o un fragmento de ?sta, donde el polinucle?tido que codifica NY?ESO?1 o un fragmento de ?sta est? operativamente ligado a un promotor inducible.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019217704 | 2019-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP22049399A true ECSP22049399A (es) | 2022-08-31 |
Family
ID=76222293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202249399A ECSP22049399A (es) | 2019-12-02 | 2022-06-24 | C?lula vector adyuvante artificial con contenido de ny?eso?1 para usar en el tratamiento del c?ncer |
Country Status (20)
Country | Link |
---|---|
US (2) | US11672851B2 (es) |
EP (1) | EP4071240A4 (es) |
JP (1) | JPWO2021112055A1 (es) |
KR (1) | KR20220119030A (es) |
CN (1) | CN114787344A (es) |
AR (1) | AR120648A1 (es) |
AU (1) | AU2020394993A1 (es) |
BR (1) | BR112022010763A2 (es) |
CA (1) | CA3162277A1 (es) |
CL (1) | CL2022001459A1 (es) |
CO (1) | CO2022008738A2 (es) |
CR (1) | CR20220320A (es) |
DO (1) | DOP2022000108A (es) |
EC (1) | ECSP22049399A (es) |
IL (1) | IL293482A (es) |
JO (1) | JOP20220121A1 (es) |
MX (1) | MX2022006716A (es) |
PE (1) | PE20221463A1 (es) |
TW (1) | TW202134431A (es) |
WO (1) | WO2021112055A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130189302A1 (en) * | 2006-02-22 | 2013-07-25 | Riken | Immunotherapeutic method using artificial adjuvant vector cells that co-express cd1d and target antigen |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1990410T (pt) | 2006-02-22 | 2020-03-03 | Riken | Imunoterapia por utilização de uma célula capaz de co-expressar um antigénio alvo e cd1d e pulsada com um ligando de cd1d |
US20130189302A1 (en) * | 2006-02-22 | 2013-07-25 | Riken | Immunotherapeutic method using artificial adjuvant vector cells that co-express cd1d and target antigen |
JP2007261876A (ja) | 2006-03-28 | 2007-10-11 | Tdk Corp | 誘電体粒子、誘電体磁器組成物およびその製造方法 |
US9163088B2 (en) * | 2006-10-27 | 2015-10-20 | Temple University | Tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera |
JP5357782B2 (ja) * | 2007-02-21 | 2013-12-04 | バクシネックス インコーポレーティッド | 抗原負荷CD1d分子によるNKT細胞活性の調節 |
JPWO2010061930A1 (ja) | 2008-11-28 | 2012-04-26 | 独立行政法人理化学研究所 | CD1d及び標的抗原の共発現アロ細胞を用いた免疫療法 |
KR101194265B1 (ko) | 2008-12-01 | 2012-10-29 | 주식회사 한국인삼공사 | 해양심층수를 이용하여 인삼 또는 홍삼 농축액의 고미 제거방법 |
WO2011119326A2 (en) | 2010-03-25 | 2011-09-29 | 3M Innovative Properties Company | Composite layer |
US9783821B2 (en) | 2011-07-29 | 2017-10-10 | Riken | Cell for use in immunotherapy which contains modified nucleic acid construct encoding wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct |
US10316332B2 (en) * | 2011-07-29 | 2019-06-11 | Riken | Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product |
DK3326641T3 (da) * | 2015-04-22 | 2019-09-30 | Curevac Ag | Rna-holdig sammensætning til behandling af tumorsygdomme |
US20170216370A1 (en) | 2015-07-31 | 2017-08-03 | Synlogic, Inc. | Bacteria engineered to treat disorders involving propionate catabolism |
CA2996535A1 (en) | 2015-07-31 | 2017-02-09 | Synlogic, Inc. | Bacteria engineered to treat disorders involving propionate catabolism |
CA3050614A1 (en) * | 2017-03-17 | 2018-09-20 | Curevac Ag | Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy |
-
2020
- 2020-12-01 TW TW109142233A patent/TW202134431A/zh unknown
- 2020-12-01 JP JP2021562641A patent/JPWO2021112055A1/ja active Pending
- 2020-12-01 JO JOP/2022/0121A patent/JOP20220121A1/ar unknown
- 2020-12-01 BR BR112022010763A patent/BR112022010763A2/pt unknown
- 2020-12-01 CA CA3162277A patent/CA3162277A1/en active Pending
- 2020-12-01 WO PCT/JP2020/044586 patent/WO2021112055A1/ja active Application Filing
- 2020-12-01 CN CN202080084442.2A patent/CN114787344A/zh active Pending
- 2020-12-01 IL IL293482A patent/IL293482A/en unknown
- 2020-12-01 EP EP20895978.3A patent/EP4071240A4/en active Pending
- 2020-12-01 MX MX2022006716A patent/MX2022006716A/es unknown
- 2020-12-01 AU AU2020394993A patent/AU2020394993A1/en active Pending
- 2020-12-01 KR KR1020227020633A patent/KR20220119030A/ko active Search and Examination
- 2020-12-01 US US17/781,616 patent/US11672851B2/en active Active
- 2020-12-01 AR ARP200103335A patent/AR120648A1/es unknown
- 2020-12-01 CR CR20220320A patent/CR20220320A/es unknown
- 2020-12-01 PE PE2022000986A patent/PE20221463A1/es unknown
-
2022
- 2022-05-24 DO DO2022000108A patent/DOP2022000108A/es unknown
- 2022-06-02 CL CL2022001459A patent/CL2022001459A1/es unknown
- 2022-06-23 CO CONC2022/0008738A patent/CO2022008738A2/es unknown
- 2022-06-24 EC ECSENADI202249399A patent/ECSP22049399A/es unknown
-
2023
- 2023-05-15 US US18/317,358 patent/US20230330200A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112022010763A2 (pt) | 2022-08-23 |
EP4071240A1 (en) | 2022-10-12 |
US20230330200A1 (en) | 2023-10-19 |
CO2022008738A2 (es) | 2022-07-19 |
AU2020394993A1 (en) | 2022-06-09 |
KR20220119030A (ko) | 2022-08-26 |
EP4071240A4 (en) | 2024-01-17 |
MX2022006716A (es) | 2022-09-12 |
JPWO2021112055A1 (es) | 2021-06-10 |
CN114787344A (zh) | 2022-07-22 |
PE20221463A1 (es) | 2022-09-21 |
WO2021112055A1 (ja) | 2021-06-10 |
DOP2022000108A (es) | 2022-10-31 |
JOP20220121A1 (ar) | 2023-01-30 |
CR20220320A (es) | 2022-11-03 |
CL2022001459A1 (es) | 2023-02-24 |
US11672851B2 (en) | 2023-06-13 |
AR120648A1 (es) | 2022-03-09 |
US20230000965A1 (en) | 2023-01-05 |
IL293482A (en) | 2022-08-01 |
CA3162277A1 (en) | 2021-06-10 |
TW202134431A (zh) | 2021-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20170140A1 (es) | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer | |
CO2017013432A2 (es) | Compuestos de indazol-fenil-fenoxi-enamida y sus variaciones | |
ECSP17059343A (es) | ARNi VARIANTE | |
ECSP22049399A (es) | C?lula vector adyuvante artificial con contenido de ny?eso?1 para usar en el tratamiento del c?ncer | |
NI201500057A (es) | Métodos para reducir riesgos asociados con insuficiencia cardiaca y factores asociados | |
CO2019013332A2 (es) | Productos terapéuticos para la enfermedad de almacenamiento de glucógeno de tipo iii | |
BR112014006455A2 (pt) | alquilamidotiazóis, preparações cosméticas ou dermatológicas com um teor de um ou vários alquilamidotiazóis e uso de um ou vários alquilamidotiazóis | |
UY36332A (es) | Composiciones de bacillus pumilus rt1279 y metodos de uso para benefficiar el crecimiento de las plantas | |
ECSP20050981A (es) | Biomarcador predictivo de terapia de linfocitos infiltrantes de tumor y sus usos | |
CO2022000481A2 (es) | Inhibidores de enzimas | |
PE20200720A1 (es) | Compuestos bifuncionales | |
CL2020002650A1 (es) | Enzimas quinureninasa humanas y sus usos | |
AR094835A1 (es) | Péptidos bioactivos cortos que promueven la cicatrización de las heridas | |
BR112021009616A8 (pt) | Composição cicatrizante que compreende água eletrolisada e máscara de aplicação cutânea | |
CO2017010151A2 (es) | Material de implante compuesto | |
CL2023000492A1 (es) | Vector de poxviridae recombinante que expresa moléculas coestimuladoras | |
AR126239A1 (es) | Región 5 no traducida y región 3 no traducida no naturales y uso de estas | |
CO2018003759A2 (es) | Tratamiento de la neuropatía periférica diabética usando células placentarias | |
CO2021005872A2 (es) | Composiciones y métodos para la estimulación ovárica controlada | |
CL2021001172A1 (es) | Uso de tivozanib para tratar sujetos con cáncer refractario. | |
DOP2023000132A (es) | Composiciones y métodos para tratar la pérdida de audición y/o la pérdida de visión asociada a clrn1 | |
CR7622A (es) | Secuencias del control del gen de corina humano | |
CO2023016804A2 (es) | Composiciones y métodos para el tratamiento de la pérdida auditiva neurosensorial mediante el uso de sistemas de vectores duales de estereocilina | |
CO2020008885A2 (es) | Arilsulfatasa a purificada y composiciones de la misma | |
UA116043C2 (uk) | Спосіб комплексного лікування цукрового діабету 2 типу з включенням препаратів з матеріалу ембріофетального походження та виділених з нього клітин |